Literature DB >> 18046641

Management of the poor responder: the role of GnRH agonists and antagonists.

Eric S Surrey1.   

Abstract

PURPOSE: Evaluate the relative benefit of various doses and regimens of GnRH agonists (GnRHa) and antagonists (GnRHant) in the management of the poor responder.
METHODS: Review of English language publications with an emphasis on prospective randomized trials where available.
RESULTS: The lack of a uniformly applied definition of the poor responder and dearth of prospective randomized trials make data analysis difficult. Traditional GnRHa flare and long luteal phase protocols do not appear to be beneficial. Reduction of GnRHa doses, "stop" protocols, and microdose GnRHa flare regimes all appear to enhance outcomes, although the relative benefit of one approach over another has not been conclusively demonstrated. GnRHant does improve outcomes in this patient population, although, in general, pregnancy rates appear to be lower in comparison to microdose GnRHa flare regimes.
CONCLUSIONS: There is no one controlled ovarian hyperstimulation (COH) protocol which is best suited for all poor responders. Low dose GnRHa regimes appear to be most advantageous. Prediction of compromised response prior to cycle initiation by a thorough assessment of ovarian reserve as well as a careful review of past response should allow for selection of an appropriate COH protocol for each individual patient.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18046641      PMCID: PMC3455001          DOI: 10.1007/s10815-007-9180-3

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  45 in total

Review 1.  Role of gonadotropin-releasing hormone antagonists in poor responders.

Authors:  Neal G Mahutte; Aydin Arici
Journal:  Fertil Steril       Date:  2006-11-16       Impact factor: 7.329

2.  High-dose follicle-stimulating hormone stimulation at the onset of the menstrual cycle does not improve the in vitro fertilization outcome in low-responder patients.

Authors:  V C Karande; G S Jones; L L Veeck; S J Muasher
Journal:  Fertil Steril       Date:  1990-03       Impact factor: 7.329

3.  Follicular phase gonadotropin-releasing hormone agonist and human gonadotropins: a better alternative for ovulation induction in in vitro fertilization.

Authors:  J E Garcia; S L Padilla; J Bayati; T A Baramki
Journal:  Fertil Steril       Date:  1990-02       Impact factor: 7.329

4.  Short-term use of gonadotropin-releasing hormone agonist (leuprolide) for in vitro fertilization.

Authors:  K P Katayama; M Roesler; C Gunnarson; E Stehlik; S Jagusch
Journal:  J In Vitro Fert Embryo Transf       Date:  1988-12

5.  An alternate approach to controlled ovarian hyperstimulation in "poor responders": pretreatment with a gonadotropin-releasing hormone analog.

Authors:  P Serafini; B Stone; J Kerin; J Batzofin; P Quinn; R P Marrs
Journal:  Fertil Steril       Date:  1988-01       Impact factor: 7.329

6.  Suppression of the ovary using a gonadotropin releasing-hormone agonist prior to stimulation for oocyte retrieval.

Authors:  D de Ziegler; M I Cedars; D Randle; J K Lu; H L Judd; D R Meldrum
Journal:  Fertil Steril       Date:  1987-11       Impact factor: 7.329

7.  Management of poor responders: can outcomes be improved with a novel gonadotropin-releasing hormone antagonist/letrozole protocol?

Authors:  William B Schoolcraft; Eric S Surrey; Debra A Minjarez; John M Stevens; David K Gardner
Journal:  Fertil Steril       Date:  2007-05-04       Impact factor: 7.329

8.  Follicular atresia associated with concurrent initiation of gonadotropin-releasing hormone agonist and follicle-stimulating hormone for oocyte recruitment.

Authors:  R G Brzyski; S J Muasher; K Droesch; S Simonetti; G S Jones; Z Rosenwaks
Journal:  Fertil Steril       Date:  1988-12       Impact factor: 7.329

9.  Value of suppression with a gonadotropin-releasing hormone agonist prior to gonadotropin stimulation for in vitro fertilization.

Authors:  K Droesch; S J Muasher; R G Brzyski; G S Jones; S Simonetti; H C Liu; Z Rosenwaks
Journal:  Fertil Steril       Date:  1989-02       Impact factor: 7.329

10.  Exogenous gonadotropin requirements are increased in leuprolide suppressed women undergoing ovarian stimulation.

Authors:  P M Horvath; M Styler; J M Hammond; R M Shelden; E Kemmann
Journal:  Fertil Steril       Date:  1988-01       Impact factor: 7.329

View more
  5 in total

1.  Discordances between follicle stimulating hormone (FSH) and anti-Müllerian hormone (AMH) in female infertility.

Authors:  Norbert Gleicher; Andrea Weghofer; David H Barad
Journal:  Reprod Biol Endocrinol       Date:  2010-06-17       Impact factor: 5.211

2.  GnRH antagonist multiple dose protocol with oral contraceptive pill pretreatment in poor responders undergoing IVF/ICSI.

Authors:  Chung-Hoon Kim; Rae-Mi You; Hyuk-Jae Kang; Jun-Woo Ahn; Ilkyung Jeon; Ji-Won Lee; Sung-Hoon Kim; Hee-Dong Chae; Byung-Moon Kang
Journal:  Clin Exp Reprod Med       Date:  2011-12-31

3.  Does hormonal contraception prior to in vitro fertilization (IVF) negatively affect oocyte yields? A pilot study.

Authors:  David H Barad; Ann Kim; Hala Kubba; Andrea Weghofer; Norbert Gleicher
Journal:  Reprod Biol Endocrinol       Date:  2013-04-04       Impact factor: 5.211

4.  Microdose GnRH Agonist Flare-Up versus Ultrashort GnRH Agonist Combined with Fixed GnRH Antagonist in Poor Responders of Assisted Reproductive Techniques Cycles.

Authors:  Maryam Eftekhar; Farnaz Mohammadian; Fariba Yousefnejad; Parisa Khani
Journal:  Int J Fertil Steril       Date:  2013-03-03

5.  Comparison Pregnancy Outcomes Between Minimal Stimulation Protocol and Conventional GnRH Antagonist Protocols in Poor Ovarian Responders.

Authors:  Shamim Pilehvari; Ensieh ShahrokhTehraninejad; Batool Hosseinrashidi; Fatemeh Keikhah; Fedyeh Haghollahi; Elham Aziminekoo
Journal:  J Family Reprod Health       Date:  2016-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.